5AM VENTURE MANAGEMENT LLC
Q3 2026 Form 13-F

SAN FRANCISCO, CALIFORNIA
CIK 0001799883 · CRD 160395 · SEC-registered investment adviser
$297.0M Reported Value Total

5AM VENTURES reports 14 total accounts under management (AUM). There are 14 discretionary accounts valued at $1,084,259,034, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
12 funds · $947.0M gross asset value
Venture Capital Fund: $625.3M · Private Equity Fund: $271.8M · Hedge Fund: $49.9M
Source: Form ADV filed 2026-03-30
Reported value
$297.0M
Quarter over quarter
-30.0%
Holdings
16
Top-10 concentration
91.2%

Key People

Form ADV owners & control persons
Kush M Parmar
MEMBER, 5AM VENTURE MANAGEMENT, LLC
Andrew James Schwab
MEMBER, 5AM VENTURE MANAGEMENT LLC
Lauren Alison Daniel
CHIEF COMPLIANCE OFFICER, GENERAL COUNSEL

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $297.0M
Positions 16
Change in reported value +3.2%
New positions 2
Exited positions 2
Position turnover 22.2%
Top-10 concentration 91.2%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
16 $297.0M
Q2 2026 13F
Filed Aug 14, 2026
16 $287.9M
Q1 2026 13F
Filed May 15, 2026
20 $360.2M
Q4 2025 13F
Filed Feb 17, 2026
21 $318.1M
Q3 2025 13F
Filed Nov 14, 2025
25 $273.0M
Q2 2025 13F
Filed Aug 14, 2025
29 $260.1M
Q1 2025 13F
Filed May 15, 2025
31 $264.4M
Q4 2024 13F
Filed Feb 14, 2025
31 $419.1M
Q3 2024 13F
Filed Nov 14, 2024
28 $484.0M
Q2 2024 13F
Filed Aug 14, 2024
28 $447.1M
Q1 2024 13F
Filed May 15, 2024
26 $446.6M
Q4 2023 13F
Filed Feb 14, 2024
25 $377.0M
Q3 2023 13F
Filed Nov 14, 2023
26 $347.5M
Q2 2023 13F
Filed Aug 14, 2023
24 $401.4M
Q1 2023 13F
Filed May 15, 2023
24 $391.0M
Q4 2022 13F
Filed Feb 14, 2023
21 $372.1M
Q3 2022 13F
Filed Nov 14, 2022
21 $522.0M
Q2 2022 13F
Filed Aug 15, 2022
21 $404.2M
Q1 2022 13F
Filed May 16, 2022
19 $457.8M
Q4 2021 13F
Filed Feb 3, 2022
17 $532.8M

8 earlier quarters on file — choose one from the quarter menu above.

Top 16 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 LTGO LATIGO BIOTHERAPEUTICS INC $122.3M 41.19%
2 TRDA ENTRADA THERAPEUTICS INC $24.0M 8.09%
3 TYRA TYRA BIOSCIENCES INC $22.5M 7.58%
4 CAMP CAMP4 THERAPEUTICS CORP $21.3M 7.18%
5 ARTV ARTIVA BIOTHERAPEUTICS INC $16.8M 5.64%
6 PHVS PHARVARIS N V $15.2M 5.13%
7 TECX TECTONIC THERAPEUTIC INC $14.1M 4.76%
8 CLDX CELLDEX THERAPEUTICS INC NEW $13.7M 4.61%
9 ZNTL ZENTALIS PHARMACEUTICALS INC $10.9M 3.68%
10 BHVN BIOHAVEN LTD $9.9M 3.32%
11 MPLT MAPLIGHT THERAPEUTICS INC $7.6M 2.55%
12 SLN SILENCE THERAPEUTICS PLC $5.2M 1.75%
13 ALXO ALX ONCOLOGY HLDGS INC $4.2M 1.43%
14 TARA PROTARA THERAPEUTICS INC $4.2M 1.41%
15 EYPT EYEPOINT INC $3.4M 1.16%
16 SKYEZZZZ SKYE BIOSCIENCE INC $1.6M 0.53%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings